RxDoctor Payments Data

Divya Rao, MD

Internal Medicine · Greer, SCNPI 1851658041

Payments from drug & device makers

$8,790in general payments, 2019–2025

Across 594 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$962
  • Amgen$620
  • Lilly USA, LLC$502
  • Pfizer$479
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,790 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$166,221
Medicare patients
213
Services billed
2,758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$78,496
FarxigaDapagliflozin Propanediol69$66,154
JardianceEmpagliflozin53$61,750
EliquisApixaban56$47,491
RybelsusSemaglutide25$37,988
MounjaroTirzepatide30$37,910
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$29,382
XareltoRivaroxaban22$22,044
Nurtec OdtRimegepant Sulfate11$16,857
Breo ElliptaFluticasone/Vilanterol30$15,380
Repatha SureclickEvolocumab18$11,707
Aimovig AutoinjectorErenumab-Aooe15$11,466
TrulicityDulaglutide12$11,368
MyrbetriqMirabegron19$11,173
Spiriva RespimatTiotropium Bromide12$6,507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,181$116,48397 claims
PfizerEliquis, Nurtec Odt, Premarin$479$69,58083 claims
Boehringer IngelheimJardiance, Spiriva Respimat$464$68,25865 claims
AstraZenecaFarxiga$962$66,15469 claims
Lilly USA, LLCMounjaro, Trulicity$502$49,27942 claims
Johnson & JohnsonXarelto$122$22,04422 claims
GSKBreo Ellipta$407$15,38030 claims
Astellas Pharma US IncMyrbetriq$160$11,17319 claims
AbbVieCreon, Synthroid$1,308$6,11531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →